Genmab ( (GMAB) ) has issued an announcement.
On April 15, 2025, Genmab A/S announced that the net sales of DARZALEX® (daratumumab) for the first quarter of 2025 totaled USD 3,237 million, with USD 1,829 million from the U.S. and USD 1,409 million from the rest of the world. Genmab receives royalties from these sales under its exclusive license agreement with Johnson & Johnson, which develops, manufactures, and commercializes daratumumab. This announcement highlights Genmab’s strong market positioning and the significant financial impact of DARZALEX sales on its operations.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab demonstrates strong financial performance with excellent revenue growth and profitability. The company’s strategic investments and robust pipeline support long-term prospects. While technical indicators show a short-term downward trend, the stock might rebound due to its underlying strength. Valuation appears reasonable, supporting a positive outlook.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics. Established in 1999, the company has a strong presence in North America, Europe, and Asia Pacific, and is known for its next-generation antibody technology platforms. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, and other advanced therapeutics aimed at transforming the lives of patients with cancer and other serious diseases.
YTD Price Performance: -8.00%
Average Trading Volume: 1,643,942
Technical Sentiment Signal: Buy
Current Market Cap: $11.88B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.